Phase I trials in oncology: Pros and cons of current designs
Publié le
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Publié le
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Publié le
With some of the recently developed drugs showing unprecedented response rates and consistent improvement in overall survival in some indications,…
Publié le
IDDI presenting two sessions at the Clinical Trials Annual Meeting The 42ND ANNUAL MEETING of the Society for Clinical Trials…
Publié le
At IDDI, statistical methodology is at the heart of every clinical study, driving study design, protocol development, clinical data collection,…
Publié le
IDDI contributed to the Pharmavoice article: Commanders & Chiefs: Clinical Services C-Suite, February, 2021 CROs and other clinical services companies…
Publié le
Improvements in the treatment of patients with cancer largely depend on clinical trials comparing a new intervention with a previous…
Publié le
IDDI Complimentary Webinar on characteristics of Covid-19 trials and impact of the pandemic on clinical trials The current SARS-CoV-2-induced…
Publié le
IDDI Complimentary Webinar on the need for integration of biomarker and IVD validation in clinical development Drug development in many…
Publié le
IDDI Complimentary Webinar on Immuno-Oncology Immuno-oncology is a buoyant field of research, with recently developed drugs showing unprecedented response rates…
Publié le
Adaptations to tumor response and progression criteria for immune therapies. Abstract Immuno-oncology is a buoyant field of research, with recently…